stocks logo

AYTU

Aytu Biopharma Inc
$
2.540
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.540
Open
2.540
VWAP
--
Vol
2.82K
Mkt Cap
22.80M
Low
2.540
Amount
--
EV/EBITDA(TTM)
4.07
Total Shares
5.97M
EV
26.05M
EV/OCF(TTM)
--
P/S(TTM)
0.24
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
15.79M
-2.69%
--
--
15.73M
-5.1%
--
--
17.92M
-0.3%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Aytu BioPharma, Inc. (AYTU) for FY2025, with the revenue forecasts being adjusted by -2.4% over the past three months. During the same period, the stock price has changed by 88.15%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.4%
In Past 3 Month
Stock Price
Go Up
up Image
+88.15%
In Past 3 Month
3 Analyst Rating
up Image
280.71% Upside
Wall Street analysts forecast AYTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AYTU is 9.67 USD with a low forecast of 8.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image
280.71% Upside
Current: 2.540
sliders
Low
8.00
Averages
9.67
High
12.00
Lake Street
Buy
initiated
$8
2025-07-01
Reason
Lake Street initiated coverage of Aytu BioPharma with a Buy rating and $8 price target. The firm beleives new entrants can make a dent in the crowded antidepressant market, particularly those that have some level of differentiation, the analyst tells investors in a research note. The firm's research indicates strong interest in Aytu's EXXUA as an alternative for patients with major depressive disorder, and says the launch will materially alter Aytu's financial profile, powering revenues to record levels already in FY27. Lake Street adds that substantial upside remains as generic overhang is resolved "one way or the other" and the EXXUA launch performance ramps at or above expectations.

Valuation Metrics

The current forward P/E ratio for Aytu Biopharma Inc (AYTU.O) is -3.13, compared to its 5-year average forward P/E of -2.16. For a more detailed relative valuation and DCF analysis to assess Aytu Biopharma Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.16
Current PE
-3.13
Overvalued PE
4.23
Undervalued PE
-8.54

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.36
Current EV/EBITDA
-10.52
Overvalued EV/EBITDA
8.51
Undervalued EV/EBITDA
-11.23

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.53
Current PS
0.35
Overvalued PS
1.17
Undervalued PS
-0.11

Financials

Annual
Quarterly
FY2025Q3
YoY :
+31.57%
18.45M
Total Revenue
FY2025Q3
YoY :
-278.94%
2.42M
Operating Profit
FY2025Q3
YoY :
-272.20%
3.94M
Net Income after Tax
FY2025Q3
YoY :
-140.38%
0.21
EPS - Diluted
FY2025Q3
YoY :
+2468.50%
-6.52M
Free Cash Flow
FY2025Q3
YoY :
-4.31%
64.42
Gross Profit Margin - %
FY2025Q3
YoY :
-165.21%
-7.03
FCF Margin - %
FY2025Q3
YoY :
-230.90%
21.35
Net Margin - %

Trading Trends

Insider
Insiders areBuying! The selling amount has increased 541.02% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
125.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
19.5K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

AYTU News & Events

Events Timeline

2025-06-30 (ET)
2025-06-30
05:19:35
Aytu BioPharma initiated with a Buy at Ascendiant
select
2025-06-25 (ET)
2025-06-25
08:27:07
Aytu BioPharma appoints Gerwin Westfield as SVP, scientific affairs
select
2025-06-23 (ET)
2025-06-23
09:00:28
Aytu BioPharma expands, extends lending agreement with Eclipse
select
Sign Up For More Events

News

4.0
06-30Benzinga
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
4.0
06-30Benzinga
Ascendiant Capital Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $12
8.5
06-10NASDAQ.COM
Aytu BioPharma Closes $16.6 Mln Offering To Support EXXUA Launch For Major Depressive Disorder
Sign Up For More News

FAQ

arrow icon

What is Aytu Biopharma Inc (AYTU) stock price today?

The current price of AYTU is 2.54 USD — it has increased 0 % in the last trading day.

arrow icon

What is Aytu Biopharma Inc (AYTU)'s business?

arrow icon

What is the price predicton of AYTU Stock?

arrow icon

What is Aytu Biopharma Inc (AYTU)'s revenue for the last quarter?

arrow icon

What is Aytu Biopharma Inc (AYTU)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Aytu Biopharma Inc (AYTU)'s fundamentals?

arrow icon

How many employees does Aytu Biopharma Inc (AYTU). have?

arrow icon

What is Aytu Biopharma Inc (AYTU) market cap?